UY37262A - [8-(fenilsulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il](1h-1,2,3-triazol-4-il)metanonas - Google Patents

[8-(fenilsulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il](1h-1,2,3-triazol-4-il)metanonas

Info

Publication number
UY37262A
UY37262A UY0001037262A UY37262A UY37262A UY 37262 A UY37262 A UY 37262A UY 0001037262 A UY0001037262 A UY 0001037262A UY 37262 A UY37262 A UY 37262A UY 37262 A UY37262 A UY 37262A
Authority
UY
Uruguay
Prior art keywords
compounds
disorders
triazol
oct
diazabiciclo
Prior art date
Application number
UY0001037262A
Other languages
English (en)
Inventor
Holger Siebeneicher Dr
Reinhard Nubbemeyer Dr
Holger Steuber
Antonius Ter Laak Dr
Antje Rottmann Dra
Michaele Peters Dra
Andrea Wagenfeld Dra
Ildiko Terebesi Dr
Horst Irlbacher Dr
Marcus Koppitz Dr
Benjamin Bader Dr
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY37262A publication Critical patent/UY37262A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención abarca los compuestos de [8–(fenilsulfonil)–3,8– diazabiciclo[3.2.1]oct–3–il](1H–1,2,3–triazol–4–il)metanona de fórmula general (I): en la cual R1, R2, R3, R4 y R5 son según lo definido en la presente invención, métodos para preparar dichos compuestos, compuestos intermedios útiles para preparar dichos compuestos, composiciones y combinaciones farmacéuticas que comprenden dichos compuestos y el uso de dichos compuestos para la manufactura de composiciones farmacéuticas para el tratamiento o profilaxis de trastornos, en particular de trastornos ginecológicos, trastornos hiperproliferativos, trastornos metabólicos, o trastornos inflamatorios como un agente único o en combinación con otros ingredientes activos.
UY0001037262A 2016-05-26 2017-05-26 [8-(fenilsulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il](1h-1,2,3-triazol-4-il)metanonas UY37262A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16171538 2016-05-26
EP16178891 2016-07-11

Publications (1)

Publication Number Publication Date
UY37262A true UY37262A (es) 2018-01-02

Family

ID=58765840

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037262A UY37262A (es) 2016-05-26 2017-05-26 [8-(fenilsulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il](1h-1,2,3-triazol-4-il)metanonas

Country Status (25)

Country Link
US (1) US10167293B2 (es)
EP (1) EP3464288B1 (es)
JP (1) JP6918020B2 (es)
KR (2) KR102373202B1 (es)
CN (4) CN114702503B (es)
AU (1) AU2017269871B2 (es)
BR (1) BR112018074381B1 (es)
CA (1) CA3025420A1 (es)
CY (1) CY1123955T1 (es)
DK (1) DK3464288T3 (es)
ES (1) ES2856964T3 (es)
HR (1) HRP20210424T1 (es)
HU (1) HUE053438T2 (es)
IL (1) IL262982B (es)
LT (1) LT3464288T (es)
MX (1) MX2018014541A (es)
PE (1) PE20190204A1 (es)
PL (1) PL3464288T3 (es)
RS (1) RS61520B1 (es)
SA (1) SA518400501B1 (es)
SG (1) SG11201809469QA (es)
SI (1) SI3464288T1 (es)
TW (1) TWI738782B (es)
UY (1) UY37262A (es)
WO (1) WO2017202817A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201825478A (zh) * 2016-12-19 2018-07-16 德商拜耳製藥公司 ［４－（苯基磺醯基）哌嗪－１－-基］（１ｈ－１，２，３－三唑－４-基）甲酮
JP7178075B2 (ja) * 2018-03-22 2022-11-25 株式会社ユニバーサルコーポレーション Ａｋｒ１ｃ３選択的阻害剤及びその用途
CN110183455B (zh) * 2019-06-18 2021-04-20 中国医科大学 氮杂双环[3.2.1]辛-3-酮类化合物及其制备方法与其用途
WO2021000862A1 (zh) 2019-07-01 2021-01-07 深圳艾欣达伟医药科技有限公司 Akr1c3抑制剂及医药用途
UY38806A (es) * 2019-08-01 2021-02-26 Novartis Ag Compuestos inhibidores tricíclicos de kars dependientes de akr1c3, composiciones y sus usos

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9908592A (pt) 1998-03-11 2001-04-24 Endorech Inc Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit
WO2008133766A1 (en) * 2007-02-16 2008-11-06 Pacific Arrow Limited Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof
JP5093096B2 (ja) * 2006-03-02 2012-12-05 アステラス製薬株式会社 １７βＨＳＤｔｙｐｅ５阻害剤
US20070259879A1 (en) 2006-03-06 2007-11-08 Trimeris, Inc. Piperazine and piperidine biaryl derivatives
MX2008012064A (es) 2006-03-23 2008-12-17 Amgen Inc Compuestos de amida 1-fenilsulfonil-diaza-heterociclica y sus usos como moduladores de hidroxiesteroide deshidrogenadas.
AU2007240364A1 (en) * 2006-04-21 2007-11-01 Smithkline Beecham Corporation IL-8 receptor antagonists
MX2009000513A (es) * 2006-07-14 2009-03-09 Genelabs Tech Inc Agentes antivirales.
US20090247499A1 (en) 2006-08-21 2009-10-01 Fletcher Joan M Sulfonylated piperazines as cannabinoid-1 receptor modulators
EP2211616A4 (en) * 2007-11-26 2011-07-13 Eisai R&D Man Co Ltd PROCESS FOR PREPARING IMIDAZOAZEPINONE COMPOUNDS
JP5578498B2 (ja) * 2009-11-10 2014-08-27 国立大学法人 千葉大学 抗癌剤キット及び抗癌剤効果増強剤
DE102011083725A1 (de) 2011-09-29 2013-04-04 Bayer Pharma AG Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
US9346803B2 (en) 2011-10-17 2016-05-24 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
WO2013142390A1 (en) 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
PE20150353A1 (es) 2012-07-10 2015-03-28 Bayer Pharma AG Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
MX2015001880A (es) * 2012-08-16 2015-05-11 Bayer Pharma AG 2,3-benzodiacepinas.
WO2014039820A1 (en) 2012-09-07 2014-03-13 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
KR20150118153A (ko) 2013-02-21 2015-10-21 바이엘 파마 악티엔게젤샤프트 17.베타.-히드록시스테로이드 데히드로게나제 (akr1 c3)의 억제를 위한 에스트라-1,3,5(10),16-테트라엔-3-카르복스아미드
JP2015020966A (ja) * 2013-07-18 2015-02-02 岐阜市 Ａｋｒ１ｃ３阻害剤
CN106687471B (zh) * 2014-09-11 2018-10-30 拜耳医药股份公司 3-氮或者硫取代的雌甾-1,3,5(10),16-四烯akr1c3抑制剂

Also Published As

Publication number Publication date
WO2017202817A1 (en) 2017-11-30
IL262982B (en) 2022-03-01
RS61520B1 (sr) 2021-03-31
TW201742868A (zh) 2017-12-16
CY1123955T1 (el) 2022-05-27
SA518400501B1 (ar) 2022-01-16
US20170342082A1 (en) 2017-11-30
WO2017202817A9 (en) 2018-12-06
SG11201809469QA (en) 2018-11-29
CN109311898A (zh) 2019-02-05
SI3464288T1 (sl) 2021-03-31
CN114702503A (zh) 2022-07-05
CN114699414A (zh) 2022-07-05
DK3464288T3 (da) 2021-03-08
HUE053438T2 (hu) 2021-06-28
US10167293B2 (en) 2019-01-01
IL262982A (en) 2018-12-31
US20180319807A2 (en) 2018-11-08
ES2856964T3 (es) 2021-09-28
BR112018074381B1 (pt) 2024-01-23
AU2017269871B2 (en) 2021-05-20
HRP20210424T1 (hr) 2021-04-30
EP3464288B1 (en) 2020-12-23
LT3464288T (lt) 2021-01-25
KR20220035507A (ko) 2022-03-22
JP6918020B2 (ja) 2021-08-11
EP3464288A1 (en) 2019-04-10
KR20190009318A (ko) 2019-01-28
TWI738782B (zh) 2021-09-11
CN114699413A (zh) 2022-07-05
AU2017269871A1 (en) 2018-11-15
MX2018014541A (es) 2019-03-28
JP2019516763A (ja) 2019-06-20
KR102373202B1 (ko) 2022-03-10
PL3464288T3 (pl) 2021-07-12
BR112018074381A2 (pt) 2019-03-06
KR102509150B1 (ko) 2023-03-10
CA3025420A1 (en) 2017-11-30
CN114702503B (zh) 2023-12-22
PE20190204A1 (es) 2019-02-05
CN109311898B (zh) 2022-04-12

Similar Documents

Publication Publication Date Title
UY37262A (es) [8-(fenilsulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il](1h-1,2,3-triazol-4-il)metanonas
DOP2019000110A (es) 1,2,4–triazolonas 2,4,5–trisustituidas
DOP2018000226A (es) Nuevos derivados de pirazolopirimidina
DOP2019000117A (es) Nuevos derivados de quinolina
DOP2020000023A (es) Nuevos derivados de quinolina
NI201900085A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
CO2019014484A2 (es) Nuevos derivados de azaquinolina
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
UY37971A (es) Derivados de indol macrocíclicos sustituidos
UY38226A (es) Nuevos derivados de quinolina
UY37972A (es) Derivados de indol macrocíclicos sustituidos con cloro
UY38816A (es) Nuevos derivados de isoquinolina
UY37973A (es) Derivados de indol macrocíclicos
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
ECSP19026563A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos
UY37530A (es) [4-(fenilsulfonil)piperazin-1-il](1h-1,2,3-triazol-4-il)metanonas
EA201892684A1 (ru) [8-(фенилсульфонил)-3,8-диазабицикло[3.2.1]окт-3-ил](1н-1,2,3-триазол-4-ил)метаноны
UY37032A (es) Compuestos de heteroarilbenzimidazol
WO2018114677A3 (en) [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230612